Skip to main content

Tata Consumer share price up 3% on plans to buy Coffee Day's vending business

The board of Tata Consumer Products has approved a proposal to evaluate the buyout and is planning a non-binding bid, reports in a section of media have said.

Tata Consumer Products share price gained more than 3 percent intraday on September 25 following reports that the company was planning a non-binding bid for the vending machine business of Coffee Day Enterprises Ltd.



The board of Tata Consumer Products has approved a proposal to evaluate the buyout and is planning a non-binding bid, a Bloomberg report said.

CDEL, which owns the Cafe Coffee Day chain, is asking for $271 million valuation for the vending-machine business, sources told the news agency.

The stock was trading at Rs 506.95, up Rs 18.20, or 3.72 percent. It has touched an intraday high of Rs 511.95 and an intraday low of Rs 495.20. It witnessed a spurt in volume by more than 1.06 times and was trading with volumes of 155,000 shares.

Coffee Day is looking to induct strategic and financial partners into businesses as part of an ongoing reconstructing exercise, a representative told Bloomberg. A representative for Tata Consumer had not responded to a request for comment.

The discussions with Tata Consumer are in early stages and CDEL is also in talks with other potential buyers for the business, the report said.

Coffee Day Group has been working on selling its assets to clear its debt. In March, it sold its Global Village Technology Park to Blackstone Group for Rs 2,700 crore.

The Tata Group has a presence in the coffee chains space through a joint venture with Starbucks in India.

Source- Moneycontrol.com

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...
Post a Comment
Read more

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...
Post a Comment
Read more